Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

PURPOSE: There are no known effective medical treatments for refractory MPNST. Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR (mammalian target of rapamycin) signaling and angiogenesis, which contributes to disease progression. We conducted a phase II study for pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sarcoma
Main Authors: Widemann, Brigitte C., Lu, Yao, Reinke, Denise, Okuno, Scott H., Meyer, Christian F., Cote, Gregory M., Chugh, Rashmi, Milhem, Mohammed M., Hirbe, Angela C., Kim, AeRang, Turpin, Brian, Pressey, Joseph G., Dombi, Eva, Jayaprakash, Nalini, Helman, Lee J., Onwudiwe, Ndidi, Cichowski, Karen, Perentesis, John P.
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2019
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6681622/
https://ncbi.nlm.nih.gov/pubmed/31427883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/7656747
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados